Holen Sie sich die Stockscreener-App
0.769
0.11%
0.0148
Schlusskurs vom Vortag:
$0.7542
Offen:
$0.7542
24-Stunden-Volumen:
12,195
Relative Volume:
0.07
Marktkapitalisierung:
$39.19M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
76.90
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
+7.70%
1M Leistung:
-8.17%
6M Leistung:
-41.02%
1J Leistung:
-46.07%
1-Tages-Spanne:
$0.7356
$0.7756
1-Wochen-Bereich:
$0.719
$0.829
52-Wochen-Spanne:
$0.5052
$1.72
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.747 | 39.19M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.68 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.20 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.80 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
231.24 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus
Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa
Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan
A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga
Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire
Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia
Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Spero Therapeutics Takes Stage at Major TD Cowen Healthcare Conference - StockTitan
Can Spero Therapeutics' Rare Disease Pipeline Impress Investors at Major Healthcare Conference? - StockTitan
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Spero therapeutics CFO sells $16,137 in stock By Investing.com - Investing.com Nigeria
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock By Investing.com - Investing.com Australia
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):